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ABSTRACT 
 
Objectives: To examine the prevalence and determinants of iron supplement use and 
the amount of iron consumed from iron-containing supplements.   
Methods:  A cross-sectional survey was performed in antenatal clinics in two tertiary 
hospitals in Sydney, Australia between January and March 2014.   
Results: Of 612 (91% response rate) pregnant women, 589 with complete data were 
analysed. The overall prevalence of iron-containing supplement use was 88.0%, of 
which 70.1% was MV only, 7.2% was iron-only and 22.2% was both.  Use of iron-
containing supplements was associated with increased gestational age, a diagnosis of 
anaemia or iron deficiency (ID) in the current pregnancy and pre-pregnancy use of an 
iron-containing supplement. Several risk factors for ID or anaemia such as  on-red 
meat eating and previous miscarriage were not associated with current iron 
supplement use. About 65% of women diagnosed with ID, and 62.3% of women 
diagnosed with anaemia were taking an iron-only supplement, with or without a MV. 
The proportion of women consuming low (<30), preventative (30-99) and treatment 
(≥100) mg/day doses were 36.8%, 45.4%, and 17.8%, respectively.  Only 46.7% of 
women diagnosed with ID were taking ≥100 mg/day iron from supplements, while 
23.3% were taking <30 mg/day.  
Conclusion: Women are consuming varying doses of iron and some high-risk women 
are taking inadequate doses of iron to prevent or treat ID or iron deficiency anaemia.  
Healthcare professionals are best positioned to advise women on iron supplement use 
in pregnancy and should educate women individually about the type and dose of 
supplement best suited to their needs.  
Keywords: iron, supplement, pregnancy, iron deficiency  
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INTRODUCTION 
 
It is well established that women are at increased risk of iron deficiency (ID) during 
pregnancy and are often unable to meet the increased iron requirements of pregnancy 
from dietary sources alone.1  Dietary reference values for iron intake during 
pregnancy vary by geographical region.  In Australia, the recommended daily intake 
for iron in pregnancy is 27 mg/day,2 which is similar to other developed countries.3  
However, like in other developed countries (USA/Canada, United Kingdom, Europe, 
New Zealand, and Japan), data from Australian pregnant women indicate that dietary 
iron intakes are below national nutrient recommendations.3  
 
There is strong evidence that iron supplementation in pregnancy improves maternal 
iron status and reduces the risk of iron deficiency anaemia (IDA).4 In fact, the 
provision of iron supplements to pregnant women is one of the most widely practiced 
public health measures.5  However, there is no consensus worldwide regarding the 
optimum iron dose for supplementation during pregnancy, with recommendations 
varying between 30 to 200 mg/day.6 Recommendations not only vary by iron dose, 
but also by whether iron supplementation is routine (treatment of all pregnant women 
regardless of their iron status) or selective (only women with or at risk of developing 
ID or IDA), and by whether guidelines include specific doses for prevention versus 
treatment of anaemia and/or ID.   
 
The International Nutritional Anemia Consultative Group (INACG) and the World 
Health Organization (WHO) both recommend universal supplementation in 
pregnancy with 60 mg of elemental iron daily for the prevention of ID, and if anaemia 
is detected, treatment with 120 mg of iron daily for three months.7    
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Among developed countries, the United States, Canada, and France recommend 
routine iron supplementation in pregnancy with 30–60 mg of elemental iron daily.8,9  
Other developed countries, such as the United Kingdom, Germany, Norway, New 
Zealand, and Australia recommend selective iron supplementation; however few of 
these countries provide guidance on the dose of supplemental iron.10  The UK 
recommends 65 mg of elemental iron daily for non-anaemic women at increased risk 
of iron depletion (i.e. women with previous anaemia, multiple pregnancy, consecutive 
pregnancies with less than a year’s interval between, and vegetarians). 11  The 
recommended dosage of daily elemental iron to treat IDA is 120 mg in the US,8 100-
200 mg in the UK11 and 100 mg in Norway.12  
 
In Australia, there are no national guidelines that provide recommendations on dosage 
of iron supplementation during pregnancy.  The Royal Australian and New Zealand 
College of Obstetricians and Gynaecologists (RANZCOG) recommend investigation 
and treatment of anaemia using haemoglobin levels at the first antenatal visit and 
again at approximately 28 weeks’ gestation, as well as iron supplementation for 
pregnant women at particular risk of ID, including vegetarians and women with 
multiple pregnancies.13  A wide range of pregnancy supplements with iron alone or in 
combination with other minerals and vitamins are commercially available on the 
market in Australia and each preparation varies in the amount of contained elemental 
iron from 5 to 105 mg.   
 
Information on iron supplement use among Australian pregnant women is limited to 
prevalence data from older studies in single hospital settings.14,15  Contemporary data 
on the prevalence and determinants of iron supplement use as well as the number of 
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iron-containing supplements, frequency, and dose of iron consumed by pregnant 
women is needed to understand whether women requiring treatment or at particular 
risk of ID are consuming iron supplements, and whether these dosages from iron 
supplements are adequate.  
 
Therefore, the aims of the present study were to examine the prevalence and 
determinants of iron supplement use in pregnancy and to compare maternal and 
pregnancy characteristics by the amount of elemental iron consumed from iron-
containing supplements.   
 
 
METHODS 
 
Design and study population 
 
A survey on iron and dietary supplement use in pregnancy was administered to 
women of all gestational ages attending antenatal clinics of two large teaching 
hospitals in Sydney, Australia between January and March 2014.  Both hospitals, the 
Royal North Shore Hospital and the Royal Hospital for Women, have tertiary 
obstetric and neonatal facilities. To be eligible, women had to be pregnant, able to 
complete the questionnaire in English, and completing the questionnaire for the first 
time. Women were approached by the recruiter while waiting for their appointment 
and provided verbal and written information about the study. Those who consented 
returned the survey to the recruiter or into a marked box.  
 
The self-administered and anonymous survey was developed based on a review of the 
literature, existing surveys, and discussion with perinatal researchers and midwives, 
and took around 10 minutes to complete. Following a pilot study of 20 women, minor 
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modifications in the order of questions were made to improve clarity and ease of 
completion. The survey consisted of 22 items in three sections; ‘About you and your 
pregnancy’, ‘About your last pregnancy’, and ‘Dietary supplements’. The primary 
aim of the survey was to collect information on iron supplement use; however general 
information on the use of other select dietary and herbal supplements 3 months before 
and during the current pregnancy was also collected and is reported elsewhere.  Ethics 
approval was obtained from Northern Sydney Health District (HREC# 
LNR/13/HAWKE/340), with site-specific approval received from both hospital sites. 
 
Iron supplements 
Prevalence, frequency and dose of iron consumed from iron-containing supplements, 
including multivitamin (MV) and/or iron-only, in the current pregnancy was assessed 
from information collected in a table within the survey that elicited detailed 
information including the brand name, the number of weeks the supplement was 
consumed, and the number of tablets consumed per week.  Women were asked to 
report every iron-only or MV and mineral preparations consumed during the current 
pregnancy.  Common iron-only and MV and mineral preparations were listed in the 
table and blank rows were provided for women to specify other brands. Information 
collected in the table was used to determine the dose of elemental iron in each of the 
iron-containing supplements mentioned.   
 
Other maternal and pregnancy factors 
The survey also collected information on maternal and pregnancy characteristics; 
factors related to the previous pregnancy that were regarded as potential determinants 
of current iron status and/or iron supplement use, the average amount of money spent 
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per month, and main sources of information for dietary supplement use in pregnancy.  
Potential determinants (explanatory variables) of iron supplement use included those 
related to maternal characteristics (maternal age, multiple pregnancy, no previous 
children, body mass index (BMI), cigarette smoking, educational attainment, and red 
meat consumption), the previous pregnancy (miscarriage, heavy bleeding, and ID), 
the current pregnancy (gestational age, gestational diabetes, gestational hypertension, 
anaemia, or ID) and iron supplement use (iron-only or MV supplement use 3 months 
prior to pregnancy, or MV supplement use in the current pregnancy).  
 
Definitions 
The total number of iron-containing supplements consumed in the current pregnancy 
was calculated as the sum of brands reported by each woman.  Based on reporting of 
brand names of MV and iron-only supplements, woman were categorised as 
consuming MV only, iron only, both or neither.  Frequency is reported as the 
maximum number of weeks that any iron-containing supplement was used because 
women often reported multiple brands for varying number of weeks.  The dose of 
elemental iron (in mg) consumed per week from an iron-containing supplement was 
calculated by adding the dosage from each iron-only or MV and mineral preparation 
that women reported using during the current pregnancy.  To compare the amount of 
elemental iron consumed from iron-containing supplements with recommended doses 
from other developed countries,8,11,12 the average daily dose of elemental iron from 
iron-containing supplements was categorised as low dose (<30 mg), preventative dose 
(30-65 mg), intermediary dose (66-99 mg), treatment dose (100-200 mg) and high 
dose (>200 mg).  Due to the small numbers, to examine possible determinants of the 
amount of iron consumed from iron-containing supplements, categories were 
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combined and <30, 30-99 and ≥100 mg were used to define low, preventative and 
treatment dosages of daily elemental iron, respectively.  Maternal age was categorised 
into <25, 25-34, and >35 years and gestational age into ≤20, 21-26, ≥27 weeks, based 
on national guidelines of anaemia and ID testing during pregnancy.13  Body mass 
index (BMI; kg/m2) was calculated using patient reported booking weight and height, 
usually recorded at 12 weeks gestation, and categorised using international 
standards.16 
 
Statistical analysis 
Percentage tabulation and contingency tables were performed to describe study 
population characteristics and to compare maternal and pregnancy characteristics by 
current use of iron-containing supplements, type of iron-containing supplement (MV 
only, iron-only, both or neither) and by categories of average daily dosages of 
elemental iron (low, preventative and treatment).  Logistic regression analysis was 
used to compare maternal and pregnancy characteristics by type of iron-containing 
supplement, whereby the reference group was “neither” and by categories of average 
daily dosages of elemental iron, whereby the reference group was “preventative 
dosage of iron).  Multivariate logistic regression analysis was conducted to take into 
account potential confounding by explanatory variables that were statistically 
significant in the unadjusted analyses. Backward stepwise selection was performed 
whereby variables with least significance were progressively dropped from each 
model until all remaining covariates were statistically significant (2-tailed P<0.05). 
Results are presented as the odds ratio (OR) and 95% confidence intervals (CIs).  All 
analyses were performed using SAS version 9.3 (SAS Institute Inc).   
 
RESULTS 
11  
 
A total of 674 women were invited to participate, of whom 612 completed the survey 
with a response rate of 91%.  Reasons for declining included busy caring for children, 
not interested, or called into an appointment.  After excluding 26 surveys due to 
incomplete data, 589 women were included in the final analyses. The majority of 
women were aged 25 years or more (95.1%) and nearly half (45.1%) already had a 
child. Approximately two-thirds of women had attained a university undergraduate 
degree or higher (67.0%) and were more than 26 weeks gestation (64.2%) at the time 
of the survey. Based on BMI, 61.6% of women were normal weight, 10.7% were 
underweight, 17.3% were overweight, and 10.5% were obese.  Only 8 women (1.4%) 
smoked cigarettes, 9.1% reported not eating any red meat, and 14.4% had experienced 
a miscarriage in their previous pregnancy.  In the current pregnancy, 10.4% of women 
had been diagnosed with anaemia and 26.6% with ID. 
 
Based on women’s reporting of brand names of any iron-containing MV and 
primarily iron-only supplements used in the current pregnancy, the prevalence of iron 
supplement use was 88.0% (518/589).  Of these 518 women, the majority (70.1%) 
reported consuming a MV only, with 7.2% consuming an iron-only supplement and 
22.2% consuming both.   
 
Comparisons of maternal and pregnancy characteristics and iron-containing 
supplement use between current users and non-users are presented in Table 1. Of the 
156 women diagnosed with ID, 25.6% (40/156) were taking MV supplement(s) only 
and 9.6% (15/156) were taking neither iron nor MV. Of the 61 women diagnosed with 
anaemia, 32.7% women were taking MV only, and 5% were taking neither iron nor 
MV supplements. 
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Table 1 
Maternal and pregnancy characteristics by type of iron-containing supplement in the current pregnancy (n=589).1 
 Type of iron-containing supplement use in reported 
current pregnancy, N (%)  
Unadjusted odds ratio  
(95% confidence intervals)2 
MV3only 
363 (61.6) 
Iron only 
40 (6.8) 
Both 
115 (19.5) 
Neither 
71 (12.1) 
MV2 only vs. 
Neither 
Iron only vs. 
Neither 
Both vs. Neither 
Maternal characteristics      
Maternal age, years 
 <25  
 25-34 
 ≥35 
 
14 (3.9) 
210 (57.9) 
139 (38.3) 
 
3 (7.5) 
21 (52.5) 
16 (40.0) 
 
8 (7.0) 
75 (65.2) 
32 (27.8) 
 
4 (5.6) 
39 (54.9) 
28 (39.4) 
 
0.65 (0.20, 2.08) 
Reference 
0.92 (0.54, 1.57) 
 
1.39 (0.29, 6.82) 
Reference 
1.06 (0.47, 2.40) 
 
1.04 (0.30, 3.67) 
Reference 
0.59 (0.31, 1.13) 
Previous children 163 (45.0) 19 (47.5) 51 (44.4) 32 (45.1) 1.00 (0.60, 1.67) 1.10 (0.51, 2.40) 0.95 (0.53, 1.73) 
BMI categories 
 Underweight 
 Normal weight  
 Overweight or obese 
 
33 (10.0) 
214 (64.7) 
84 (25.4) 
 
4 (10.5) 
19 (50.0) 
15 (39.5) 
 
16 (14.7) 
59 (54.1) 
34 (31.2) 
 
5 (7.6) 
43 (65.2) 
18 (27.3) 
 
1.33 (0.49, 3.59) 
Reference 
0.94 (0.51, 1.72) 
 
1.81 (0.44, 7.50) 
Reference 
1.89 (0.79, 4.51) 
 
2.33 (0.79, 6.86) 
Reference 
1.38 (0.69, 2.75) 
Educational attainment 
 Less than up to year 12  
 Trade/apprenticeship/diploma 
 University or higher 
 
26 (7.3) 
88 (24.9) 
240 (67.8) 
 
2 (5.0) 
9 (22.5) 
29 (72.5) 
 
10 (8.8) 
30 (26.3) 
74 (64.9) 
 
9 (12.7) 
17 (23.9) 
45 (63.4) 
 
Reference 
1.79 (0.72, 4.49) 
1.85 (0.81, 4.20) 
 
Reference 
2.38 (0.42, 13.47) 
2.90 (0.59, 14.39) 
 
Reference 
1.59 (0.54, 4.67) 
1.48 (0.56, 3.92) 
Do not eat red meat 24 (6.7) 6 (15.0) 17 (14.9) 6 (8.6) 0.77 (0.30, 1.95) 1.88 (0.56, 6.29) 1.87 (0.70, 4.99) 
Previous pregnancy       
Previous miscarriage 39 (12.8) 4 (12.9) 16 (17.2) 12 (18.8) 1.57 (0.77, 3.21) 1.56 (0.46, 5.29) 1.11 (0.49, 2.54) 
Heavy bleeding before or after birth4 23 (6.3) 4 (10.0) 8 (7.0) 3 (4.2) 1.53 (0.45, 5.25) 2.52 (0.53, 11.87) 1.69 (0.43, 6.61) 
Diagnosed with iron deficiency 16 (4.4) 6 (15.4) 24 (20.9) 5 (7.0) 0.61 (0.22, 1.73) 2.40 (0.68, 8.45) 3.48 (1.26, 9.60) 
Current pregnancy       
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Gestational age, weeks 
 ≤ 20  
 21-26 
 ≥ 27 
 
95 (26.5) 
56 (15.6) 
208 (57.9) 
 
5 (12.5) 
3 (7.5) 
32 (80.0) 
 
6 (5.3) 
15 (13.3) 
92 (81.4) 
 
22 (31.9) 
6 (8.7) 
41 (59.4) 
 
Reference 
2.16 (0.83, 5.65) 
1.18 (0.66, 2.08) 
 
Reference 
2.20 (0.41, 11.95) 
3.43 (1.17, 10.07)* 
 
Reference 
9.17 (2.48, 33.91)* 
8.23 (3.10, 21.81)** 
Diagnosed with anaemia  20 (5.5) 10 (25.6) 28 (24.6) 3 (4.2) 1.33 (0.38, 4.58) 7.82 (2.00, 30.50)** 7.38 (2.15, 25.31)** 
Diagnosed with iron deficiency 40 (11.1) 23 (59.0) 78 (67.8) 15 (21.1) 0.47 (0.24, 0.90) 5.37 (2.28, 12.63)** 7.87 (3.94, 15.71)*** 
Supplement use 3 months before 
current pregnancy 
     
Iron supplement  29 (8.1) 5 (12.5) 23 (20.0) 2 (2.9) 3.00 (0.70, 12.85) 4.86 (0.90, 26.31) 8.50 (1.94, 37.28)** 
Multivitamin supplement  174 (48.6) 10 (25.0) 46 (40.0) 21 (30.0) 2.21 (1.27, 3.83)** 0.78 (0.32, 1.87) 1.56 (0.83, 2.93) 
1 Values represent number of women (%). Multiple pregnancies were not examined because of small and empty cell sizes.  The number (%) of women with 
multiple pregnancies consuming a multivitamin supplement only was 13 (3.6), an iron supplement only was 2 (5.0), both types of supplements was 15 (13.2) 
and neither was 0. 
2Association between maternal characteristics and pregnancy characteristics with use and type of current iron-containing supplement is reported using P-
values with the “neither” as the reference group.  * P<0.05, **P<0.01, ***P<0.001. 
3Abbreviations include MV for multivitamin. 
 4 Includes women who reported receiving blood transfusion.      
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Unadjusted analyses found that compared to non-users, woman who consumed MV 
supplements 3 months prior to pregnancy were more likely to consume MV 
supplements in the current pregnancy (Table 1).  None of the other factors were 
significant; therefore, adjusted analysis was not performed.  Compared to non-users, 
unadjusted analyses found that women ≥27 weeks gestational age and with a 
diagnosis of anaemia or ID in the current pregnancy were significantly more likely to 
consume iron-only supplement(s).  In the adjusted analyses, current diagnosis of 
anaemia (AOR 5.52, 95% CI: 1.32, 23.18, P=0.02) or ID (AOR 4.16, 95% CI: 1.70, 
10.20, P=0.002) remained statistically significant.   
 
And finally, compared to non-users, unadjusted analyses found that increased 
gestational age of 21-26 weeks or ≥27 weeks (compared to ≤ 20 weeks), a diagnosis 
of anaemia or ID in the current pregnancy and use of iron-only supplement(s) 3 
months prior to pregnancy were significantly associated with current use of both MV 
and iron-only supplement(s).  In the adjusted model, all except gestational age 
remained statistically significant such that use of both MV and iron-only 
supplement(s) in the current pregnancy was more likely among woman with a 
diagnosis of anaemia (AOR 4.08; 95% CI: 1.09, 15.29, P=0.04) or ID (AOR 6.05; 
95% CI: 2.91, 12.58, P<0.0001) in the current pregnancy and who used iron-only 
supplement(s) 3 months prior to pregnancy (AOR 9.24, 95% CI: 1.97, 43.23, 
P=0.005).  
 
Of the 432 women who provided information on the dose and frequency of 
supplements taken, the median (25th, 75th percentile) daily dose of elemental iron was 
60 mg (10.0, 64.6).  The prevalence of women consuming an average daily dose of 
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<30, 30-65, 66-99, 100-200 and >200 mg of elemental iron from iron-containing 
supplements was 36.8% (n=159), 39.6% (n=171), 5.6% (n=24), 15.1% (n=65) and 
3.0% (n=13), respectively.   
 
Descriptive statistics of maternal and pregnancy factors  and average daily intake of 
low (<30 mg), preventative (30-99 mg) or treatment (≥100 mg) dosages of elemental 
iron from iron-containing supplements; and the association between low and 
treatment dosages compared with preventative (30-99 mg) dosages of elemental iron 
are presented in Table 2.  
 
Unadjusted analyses found that women with previous children were more likely to 
consume low vs. preventative iron dosages (OR 2.09, 95% CI: 1.36, 3.20).  None of 
the other factors were significant therefore, adjusted analysis was not performed.  
Unadjusted analyses comparing women consuming preventative versus treatment 
dosages of elemental iron found statistically significant associations with the 
following explanatory variables: multiple pregnancy, BMI, diagnosis of ID in previous 
pregnancy, increased gestational age, and current pregnancy diagnosis with either anaemia or 
ID.  Adjusted analyses found that women were significantly more likely to consume 
treatment dosages of iron if they had previous children (AOR 2.15; 95% CI 1.11, 4.15, 
P=0.02) or a diagnosis of ID in the current pregnancy (AOR 13.77, 95% CI 7.06, 
26.86, P<0.0001) and significantly less likely to consume treatment dosages if that 
had consumed a MV 3 months prior to the current pregnancy (AOR 0.32; 95% CI 
0.16, 0. 64, P=0.001).  None of the other factors found to be statistically significant in 
the unadjusted analyses remained in the final model.
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Table 2 
Maternal and pregnancy characteristics according to pregnant women’s average daily intake of elemental iron from iron-containing supplements 
in the current pregnancy, for women taking iron containing supplements in whom the daily dose of iron was known (n=432).1 
 Average daily dose of elemental iron from iron-
containing supplements1 
Unadjusted odds ratio  
(95% confidence intervals) 
Low  
(<30 mg) 
n =159, 36.8% 
Preventative 
(30-99 mg) 
n =196, 45.4% 
Treatment 
(≥100 mg) 
n=77, 17.8% 
Low vs. 
preventative dose 
 Treatment vs. 
preventative dose 
 
Maternal characteristics      
Maternal age, years  
 <25 
 25-34 
 ≥35 
 
5 (3.1) 
89 (56.0) 
65 (40.9) 
 
10 (5.1) 
116 (59.2) 
70 (35.7) 
 
5 (6.5) 
47 (61.0) 
25 (32.5) 
 
0.65 (0.22, 1.98) 
Reference 
1.21 (0.78, 1.87) 
 
1.23 (0.40, 3.80) 
Reference 
0.88 (0.50, 1.56) 
Educational attainment  
 Less than up to year 12 
 Trade/apprenticeship/diploma 
 University or higher 
 
14 (8.9) 
38 (24.2) 
105 (66.9) 
 
13 (6.8) 
49 (25.8) 
128 (67.4) 
 
6 (7.8) 
18 (23.4) 
53 (68.8) 
 
Reference 
0.72 (0.30, 1.71) 
0.76 (0.34, 1.69) 
 
Reference 
0.80 (0.26, 2.41) 
0.90 (0.32, 2.49) 
Multiple pregnancy 5 (3.1) 8 (4.1) 12 (15.6) 0.76 (0.24, 2.37) 4.32 (1.69, 11.03)** 
Previous children  88 (55.4) 73 (37.2) 40 (52.0) 2.09 (1.36, 3.20)*** 1.82 (1.07, 3.10) 
BMI categories 
 Underweight 
 Normal weight 
 Overweight/obese 
 
18 (12.5) 
88 (61.1) 
38 (26.4) 
 
13 (7.1) 
124 (67.8) 
46 (25.1) 
 
11 (14.9) 
36 (48.7) 
27 (36.5) 
 
1.95 (0.91, 4.19) 
Reference 
1.16 (0.70, 1.94) 
 
2.92 (1.20, 7.06)* 
Reference 
2.02 (1.11, 3.69)* 
Do not eat red meat  11 (7.0) 16 (8.3) 11 (14.3) 0.82 (0.37, 1.83) 1.83 (0.81, 4.16) 
Previous pregnancy      
Previous miscarriage 23 (16.4) 21 (13.6) 10 (15.6) 1.26 (0.67, 2.38) 1.18 (0.52, 2.67) 
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Heavy bleeding before or after last birth2 15 (9.4) 9 (4.6) 7 (9.1) 2.16 (0.92, 5.09) 2.08 (0.75, 5.79) 
Diagnosed with iron deficiency 14 (8.9) 12 (6.2) 16 (20.8) 1.47 (0.66, 3.27) 3.96 (1.77, 8.83)** 
Current pregnancy      
Gestational age, weeks 
 ≤ 20  
 21-26 
 ≥ 27 
 
40 (25.5) 
21 (13.4) 
96 (61.2) 
 
47 (24.1) 
29 (14.9) 
119 (61.0) 
 
5 (6.6) 
10 (13.2) 
61 (80.3) 
 
Reference 
0.85 (0.42, 1.72) 
0.95 (0.58, 1.56) 
 
Reference 
3.24 (1.01, 10.43) 
4.82 (1.82, 12.74)* 
Diagnosed with anaemia  18 (11.3) 13 (6.6) 19 (25.0) 1.80 (0.85, 3.79) 4.69 (2.18, 10.09)*** 
Diagnosed with iron deficiency  28 (17.7) 36 (18.4) 56 (72.7) 0.96 (0.56, 1.65) 11.85 (6.39, 21.99)*** 
Supplement use 3 months before current pregnancy      
Iron supplement 13 (8.2) 23 (11.9) 15 (19.5) 0.66 (0.32, 1.36) 1.79 (0.88, 3.67) 
Any multivitamin supplement  75 (47.5) 96 (49.7) 21 (27.3) 0.91 (0.60, 1.39) 0.38 (0.21, 0.67) 
1Values represent number of women (%). Of 589 women, 157 were excluded because of missing information required to calculate the daily dose of elemental 
iron, such as the brand name for the iron-containing supplement(s) (n=71) or the iron frequency and number of pills consumed per week (n=86). * P<0.05, 
**P<0.01, ***P<0.001 
2 Includes women who reported receiving a blood transfusion.
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When asked for details about the type and frequency of iron-containing supplement 
use in the current pregnancy, 63.1% of women reported having consumed one 
supplement, 29.4% had consumed two supplements, and 7.5% had consumed between 
3 and 6 different brands of supplements.  Most women were consuming iron from a 
MV, with only 26.3% reporting intake from an iron-only supplement.  A list of the 
iron-containing supplements reported and the elemental dose and form of iron in each 
brand is presented in Supplementary Table 1.    
 
Supplementary Table 1 
List of iron-containing supplements that women reported using in the current 
pregnancy by MV and iron-only by type of iron and dose of elemental iron (mg).  
Type and brand of supplement Type and amount of iron Dose of 
elemental 
iron (mg) 
 
Iron-containing multivitamin supplements 
Brand A 15.7 mg of ferrous fumarate 5 
Brand B 183 mg of ferrous fumarate 60 
Brand C 14.97 mg of iron phosphate 5 
Brand D 25 mg of iron amino acid chelate 5 
   
Primarily iron-only supplements   
Brand E 60 mg of iron amino acid chelate 12 
Brand F 270 mg of ferrous sulphate 87.4 
Brand G 310 mg of ferrous fumarate 100 
Brand H 325 mg of ferrous sulphate 105 
Brand I 325 of ferrous sulphate 105 
Brand J 250 mg of ferrous sulphate 80 
 
The prevalence of women taking the three most common iron-containing MV 
supplements was 44.5% for a brand which contains 60 mg of elemental iron per tablet, 
31.5% for a brand which contains 5 mg of elemental iron per tablet, and 4.4% for a 
different brand which contains 5 mg of elemental iron per tablet.  The prevalence of 
women taking the three most common iron-only supplements was 15.3% for a brand 
which contains 105 mg of elemental iron per tablet, 2.3% for a brand which contains 
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87.4 mg of elemental iron per tablet, and 1.9% for a brand which contains 100 mg of 
elemental iron per tablet.  The median of the maximum number of weeks of 
supplement use was 20 weeks (25th, 75th percentile: 4, 30).  The average monthly 
expenditure was $43AUD,  ranging from $5 to $300; and the most common sources 
of information on dietary supplements reported by women were a woman’s doctor 
(74.3%), midwife or nurse (45.3%), and the internet (21.2%) (Figure 1). 
 
Figure 1.  Main sources of information on dietary supplements reported by pregnant 
women currently consuming an iron-containing supplement. 
 
 
 
DISCUSSION 
The present study found that the vast majority of pregnant women are consuming an 
iron-containing supplement. Women were more likely to consume an iron-containing 
supplement if they had increased gestational age, a diagnosis of anaemia or ID in the 
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current pregnancy and reported using an iron-containing supplement 3 months prior to 
the current pregnancy. However, only two thirds of women (64.7%) diagnosed with 
ID, and 62.3% of women diagnosed with anaemia were taking an iron supplement, 
with or without a MV. Less than half of women (46.7%) diagnosed with ID were 
taking ≥100 mg iron per day from supplements, and a quarter (23.3%) were taking 
<30 mg per day. Several risk factors for ID examined in this study were not associated 
with greater likelihood of iron supplement use in pregnancy, including age, multiple 
pregnancies, having previous children, BMI, educational attainment, not eating red 
meat, previous miscarriage, heavy bleeding in previous pregnancy before or after 
birth, and diagnosis with ID in previous pregnancy. Among women consuming some 
form of iron from either a MV or primarily iron-only supplement, more than a third of 
women were consuming a low dose (<30 mg), nearly half were consuming a 
preventative dose (30-99 mg) and nearly one fifth were consuming a treatment (≥100 
mg) dose of oral iron daily. Compared with preventative dosages of average daily 
elemental iron, women with previous children were more likely to take low doses. 
While high treatment dosages were more common among women with previous 
children and a diagnosis of ID in the current pregnancy and less common among those 
who consumed a MV 3 months prior to pregnancy.  
 
The prevalence of iron-containing supplement use in our study (88%) was higher than 
those reported in previous Australian studies which found a prevalence of 35% among 
pregnant women at 36-38-weeks gestation in a tertiary hospital in Melbourne in 
200314 and a prevalence of 14%, 13%, and 27% in the 1st, 2nd, and 3rd trimesters 
respectively, among women attending an antenatal clinic in Adelaide in 2001.15   
These differences may be related to how data was collected, as our study included 
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MVs containing iron in the overall prevalence estimate; however, only 7.2% of 
women were consuming an iron-only supplement and 22.2% were consuming both. 
There may also be differences in study populations and changes in the use of iron 
supplements in pregnancy over time. 
 
Our study found use of iron-containing supplements in pregnancy was not associated 
with many of the risk factors for iron supplement use such as multiple pregnancies, 
having previous children, not eating red meat and a previous miscarriage, that are  
highlighted in national recommendations by RANZCOG13 and international 
guidelines issued by the World Health Organisation on iron and folic acid 
supplementation in pregnancy.17   These data suggest that a small proportion of 
women with these risk factors require greater attention and perhaps counselling about 
the importance of adequate iron status in pregnancy. It is uncertain from our data 
whether these women at increased risk of ID are not being identified as requiring an 
iron supplement or are self-selecting not to take an iron supplement.  Most women 
reported a clinician as their main source of information, therefore efforts to improve 
awareness among this high-risk group could be achieved by providing additional 
educational materials in healthcare settings and to professionals to hand out to their 
patients.   
 
An important finding from our study is that pregnant women are consuming varying 
doses of iron from iron-containing supplements.  In our study, about 45% of women 
were consuming a daily dose of 30-99 mg of elemental iron, which is similar to the 
preventative dose of iron that is routinely recommended for all pregnant women in 
countries such as the United States, Canada and France (30-60 mg) and the 
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preventative dose (65 mg) for women at risk of or with ID in the UK.8,9,11   About 1 in 
5 women were consuming a daily dose of iron (≥100 mg) that in most developed 
countries is recommended for treatment of IDA in pregnancy.8,9,12,17  While there are 
some concerns with iron excess, such as the potential for iron, as a redox-active 
transitional metal, to trigger oxidation stress and to cause decreased absorption of 
other essential divalent metal ions, such as zinc,18 results from our study suggest very 
few Australian pregnant (~3%) women are at risk of consuming excess iron (>200 
mg/day) from iron-containing supplements.   
 
Our study did find; however, that 37% of women were consuming a low dose (<30 
mg) of daily elemental iron, some of whom had or were at high-risk for ID.  While a 
trial by Australian researchers demonstrated that a routine low-dose iron supplement 
(20 mg per day) is an effective strategy for preventing IDA and ID;6 higher doses of 
supplemental iron are required to treat IDA or ID.4  A study of Danish pregnant 
women which evaluated the effect of 20, 40, 60, and 80 mg of iron daily found 20 mg 
was inadequate to prevent ID in a substantial number of women and that 40 mg of 
iron prevented IDA in more than 95% of the women.19   
 
Our findings reveal a high prevalence of women taking popular pregnancy MVs, with 
most containing only 5 mg of elemental iron per tablet. Furthermore, it appears many 
women may not take the recommended number of tablets on a daily basis.  This may 
be problematic as many pregnant women may not be aware that the MVs they are 
purchasing may not be providing them with an adequate daily dose of iron to ensure 
optimal iron status.  Compliance with iron supplement use is also reported to be 
generally low because of the potential side effects, such as epigastric discomfort, 
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nausea, diarrhoea, and constipation.18  Pregnant women may also not be aware that 
the form of iron in supplements varies (i.e. ferrous sulfate, ferrous gluconate, ferric 
citrate), which may influence its bioavailability and possible side effects.  Certain 
forms of supplemental iron, such as heme iron polypeptides, carbonyl iron, iron 
amino-acid chelates, and polysaccharide-iron complexes, might have fewer 
gastrointestinal side effects than ferrous or ferric salts.  Elemental iron is listed on 
supplements, so consumers do not need to calculate the amount of iron supplied by 
various forms of iron supplements; however, healthcare professionals should notify 
women of what to look for when selecting the appropriate iron supplement for their 
needs.   
 
Pregnant women should also be counseled on how to consume oral iron supplements 
correctly.  Both the US and UK guidelines include such advice, such as consuming 
iron supplements on an empty stomach, an hour before meals, with a source of 
vitamin C to maximize absorption and not at the same time as other medications or 
antacids.8,11   Further research is needed to examine women’s knowledge and beliefs 
around brand choice, the required amounts of iron in pregnancy supplements and also 
what advice healthcare professionals are providing to women about what type and 
dose of iron supplements to use during pregnancy.   
 
Despite iron supplementation during pregnancy being common, there is limited 
contemporary data in Australia on iron supplement use.  Strengths of this study 
include the collection of detailed information on the frequency and dose of iron from 
iron-containing supplements on a range of maternal and pregnancy factors, and the 
inclusion of women of all gestational ages.  Limitations are the cross-sectional nature 
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of the study which limited us from examining individual and group differences over 
time, the lack of data on dietary iron intakes and use of intravenous iron.  We also do 
not know how many women received the recommendation to take iron 
supplementation by a healthcare professional, in which amount, and how many of 
them followed the recommendation. This would provide relevant information on the 
effect of the intention to treat and on the appropriateness of the amount recommended 
when comparing with the international guidelines.  Another limitation is the 
sociodemographic differences between our study population and the total state 
maternity population during the same period.20   Women in the present study were 
predominantly tertiary educated and older which, limits the generalisability of our 
study findings to all pregnant women in Australia.        
 
In summary, results from our study suggest that a small proportion of women with or 
at risk of ID are not consuming an iron-containing supplement during pregnancy.  
Women are consuming varying doses of iron and women with or at risk of ID or 
anaemia  are taking inadequate doses of iron to prevent or treat ID or IDA.  Australia 
does not have established national guidelines on preventative or prophylactic iron to 
pregnant women, and therefore it is up to healthcare professionals to advise women 
individually about the type, dose and duration of iron supplement use best suited to 
their needs.  National public health guidelines in Australia on the management and 
treatment of ID in pregnancy would help ensure greater consistency and optimal 
antenatal care around iron supplement use in pregnancy.    
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